Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simplivir
- Development stage
- Discontinued
- Lead developer
- CytoGenix
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Intravenous, Topical, Ophthalmic
01
Overview
Simplivir is an experimental DNA-based antiviral therapeutic developed by CytoGenix for the treatment of herpes simplex virus (HSV) infections. The product was designed using CytoGenix's proprietary synthetic DNA (synDNA) manufacturing technology, which aimed to produce high-purity, linear DNA sequences more efficiently than traditional plasmid-based methods. Simplivir was intended to function as either a DNA vaccine or a gene-silencing therapy to inhibit HSV replication or stimulate a targeted immune response. In 2007, CytoGenix expanded its manufacturing capabilities to support the production of Simplivir and its influenza vaccine candidates. However, the development of Simplivir appears to have been discontinued following the company's subsequent financial and legal challenges in the late 2000s.
- Brand names
- Simplivir
Beyond the preview
Go deeper on Simplivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simplivir.